Mar. 11 at 6:27 PM
$CNSP TODAY’S NEW STRATEGIC DIRECTION FOR CNSP: Planning on leveraging the trial data from Berubicin (& previous TPI287) to outside biotech or pharmaceutical cos. in return for immediate and phased in funds through out licensing agreements is where this company should have been a year ago but the previous management apparently lacked the vision or skills to implement. Now that we have totally new aggressive management and with Amy Mahery, especially, remaining on the board, I see this as very plausible and well before their cash is depleted. As they approach a deal on the above, in parallel I would expect more specifics and disclosure on where they plan to invest this money. IMHO and not investment advice.
